Key Insights

Highlights

Success Rate

90% trial completion (above average)

Published Results

11 trials with published results (6%)

Research Maturity

62 completed trials (31% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

3.6%

7 terminated out of 197 trials

Success Rate

89.9%

+3.3% vs benchmark

Late-Stage Pipeline

11%

21 trials in Phase 3/4

Results Transparency

18%

11 of 62 completed with results

Key Signals

11 with results90% success

Data Visualizations

Phase Distribution

118Total
Not Applicable (66)
Early P 1 (2)
P 1 (11)
P 2 (18)
P 3 (8)
P 4 (13)

Trial Status

Completed62
Recruiting47
Unknown44
Active Not Recruiting16
Not Yet Recruiting10
Withdrawn7

Trial Success Rate

89.9%

Benchmark: 86.6%

Based on 62 completed trials

Clinical Trials (197)

Showing 20 of 20 trials
NCT06136221Not ApplicableActive Not RecruitingPrimary

Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease

NCT05794555Phase 3CompletedPrimary

LiveSMART Trial to Prevent Falls in Patients With Cirrhosis

NCT07191886Recruiting

Measuring Patient Reported Needs in Outpatient Liver Disease Management

NCT07140120Active Not RecruitingPrimary

LiveSMART Trial to Prevent Falls in Patients With Cirrhosis - Supplementary Study

NCT07035158CompletedPrimary

DELIVER Study in a Population With Clinical Suspicion of Liver Cirrhosis

NCT05500222Phase 3Active Not Recruiting

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

NCT04867954CompletedPrimary

Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis

NCT02344680Completed

Liver Fibrosis in Zambian HIV-HBV Co-infected Patients

NCT04172779Phase 2Not Yet RecruitingPrimary

Erlotinib for Hepatocellular Carcinoma Chemoprevention

NCT04592744Phase 4Active Not RecruitingPrimary

Angiotensin 2 for AKI After OLT

NCT03158818Completed

Chronic Hepatitis B Virus Infection in Zambia

NCT07629128Active Not Recruiting

Patients With Primary Biliary Cholangitis(PBC)

NCT05832229Phase 2Recruiting

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

NCT04595474Active Not Recruiting

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes

NCT06437964Not ApplicableCompletedPrimary

Prophylactic Antibiotics in Endoscopic Secondary Prevention of Gastroesophageal Variceal Bleeding

NCT07585786Not Yet RecruitingPrimary

Effect of LSD on Renal Function in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)

NCT07588334Not Yet RecruitingPrimary

Effect of LSD on Lipid Profiles in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)

NCT05786482Not ApplicableCompleted

Evidence Based Mental Wellness Programming Online for Adults Across Chronic Physical Conditions

NCT06950788RecruitingPrimary

Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant

NCT04199910SuspendedPrimary

4beta-hydroxycholesterol in Cirrhosis

Scroll to load more

Research Network

Activity Timeline